TC Biopharm (TCBP) Competitors $0.68 -0.86 (-55.78%) Closing price 03/21/2025Extended Trading$0.68 0.00 (0.00%) As of 03/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock TCBP vs. EVFM, NMTR, WINT, TRVN, ENVB, TNFA, GRI, VIRX, BIOR, and MYMDShould you be buying TC Biopharm stock or one of its competitors? The main competitors of TC Biopharm include Evofem Biosciences (EVFM), 9 Meters Biopharma (NMTR), Windtree Therapeutics (WINT), Trevena (TRVN), Enveric Biosciences (ENVB), TNF Pharmaceuticals (TNFA), GRI Bio (GRI), Viracta Therapeutics (VIRX), Biora Therapeutics (BIOR), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "pharmaceutical products" industry. TC Biopharm vs. Evofem Biosciences 9 Meters Biopharma Windtree Therapeutics Trevena Enveric Biosciences TNF Pharmaceuticals GRI Bio Viracta Therapeutics Biora Therapeutics MyMD Pharmaceuticals Evofem Biosciences (NASDAQ:EVFM) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Which has preferable valuation and earnings, EVFM or TCBP? Evofem Biosciences has higher revenue and earnings than TC Biopharm. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvofem Biosciences$11.39M0.09$52.98M-$0.21-0.04TC Biopharm$4.76M0.06-$7.35MN/AN/A Is EVFM or TCBP more profitable? TC Biopharm has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. TC Biopharm's return on equity of 0.00% beat Evofem Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Evofem Biosciences-46.42% -91.97% -61.93% TC Biopharm N/A N/A N/A Does the MarketBeat Community favor EVFM or TCBP? Evofem Biosciences received 260 more outperform votes than TC Biopharm when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 66.67% of users gave TC Biopharm an outperform vote. CompanyUnderperformOutperformEvofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% TC BiopharmOutperform Votes266.67% Underperform Votes133.33% Do insiders & institutionals believe in EVFM or TCBP? 0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 16.3% of TC Biopharm shares are held by institutional investors. 0.2% of Evofem Biosciences shares are held by company insiders. Comparatively, 15.4% of TC Biopharm shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer EVFM or TCBP? In the previous week, Evofem Biosciences had 2 more articles in the media than TC Biopharm. MarketBeat recorded 2 mentions for Evofem Biosciences and 0 mentions for TC Biopharm. Evofem Biosciences' average media sentiment score of 0.00 equaled TC Biopharm'saverage media sentiment score. Company Overall Sentiment Evofem Biosciences Neutral TC Biopharm Neutral Do analysts recommend EVFM or TCBP? TC Biopharm has a consensus target price of $48.00, indicating a potential upside of 6,948.46%. Given TC Biopharm's stronger consensus rating and higher probable upside, analysts clearly believe TC Biopharm is more favorable than Evofem Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00TC Biopharm 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, EVFM or TCBP? Evofem Biosciences has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. SummaryTC Biopharm beats Evofem Biosciences on 9 of the 15 factors compared between the two stocks. Get TC Biopharm News Delivered to You Automatically Sign up to receive the latest news and ratings for TCBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCBP vs. The Competition Export to ExcelMetricTC BiopharmBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$279,000.00$2.84B$5.31B$7.35BDividend YieldN/A1.86%5.45%4.34%P/E RatioN/A30.4821.9417.82Price / Sales0.06441.91380.6697.73Price / CashN/A168.6838.2534.64Price / Book0.003.466.453.98Net Income-$7.35M-$72.06M$3.22B$247.81M7 Day PerformanceN/A2.57%5.85%3.19%1 Month Performance-55.78%-15.93%-9.62%-7.70%1 Year Performance-99.71%-25.72%11.79%1.49% TC Biopharm Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCBPTC Biopharm1.2558 of 5 stars$0.68-55.8%$48.00+6,948.5%-99.7%$279,000.00$4.76M0.0080High Trading VolumeEVFMEvofem Biosciences0.2276 of 5 stars$0.01-2.1%N/A-41.6%$1.05M$11.39M-0.01120News CoverageGap UpNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220WINTWindtree Therapeutics1.4109 of 5 stars$1.36+2.3%$350.00+25,635.3%-99.6%$997,000.00N/A-0.0830TRVNTrevena1.2726 of 5 stars$1.11-1.8%$5.00+350.5%-87.3%$959,000.00$443,000.00-0.0240Analyst ForecastNews CoverageENVBEnveric Biosciences2.7413 of 5 stars$1.27+1.6%$10.00+687.4%-91.1%$847,000.00N/A-0.0320Short Interest ↓Positive NewsTNFATNF PharmaceuticalsN/A$0.27-2.0%N/AN/A$745,000.00N/A0.006Earnings ReportNews CoveragePositive NewsGap UpGRIGRI Bio2.2402 of 5 stars$1.51+13.5%$115.50+7,549.0%-98.7%$699,000.00N/A-0.131Short Interest ↑Analyst RevisionVIRXViracta Therapeutics1.0936 of 5 stars$0.02+14.3%$4.05+20,150.0%-98.2%$696,000.00N/A-0.0220BIORBiora TherapeuticsN/A$0.15+21.7%$23.00+15,131.8%-98.1%$683,000.00$892,000.00-0.01120Gap UpMYMDMyMD PharmaceuticalsN/A$0.28+7.1%N/A-92.7%$654,000.00N/A0.006High Trading Volume Related Companies and Tools Related Companies Evofem Biosciences Alternatives 9 Meters Biopharma Alternatives Windtree Therapeutics Alternatives Trevena Alternatives Enveric Biosciences Alternatives TNF Pharmaceuticals Alternatives GRI Bio Alternatives Viracta Therapeutics Alternatives Biora Therapeutics Alternatives MyMD Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCBP) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share TC Biopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCBP Stock Free TCBP Stock Alerts